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INITIAL EXPERIENCE OF INTRAOPERATIVE IDENTIFICATION OF 
PARATHYROID GLANDS WITH ELASTIC SCATTERING SPECTROSCOPY 
 
JUSTIN LEE GILLIS 
 
ABSTRACT 
Background: Postoperative hypoparathyroidism due to damage to the parathyroid glands 
during a thyroidectomy is a well-known surgical complication.  The current gold standard 
intraoperative method for identifying parathyroid glands is surgical judgment; other 
methods are limited in both their sensitivity and convenience.  There is a clear need for 
an objective diagnostic tool that is effective in its identification of the parathyroid glands 
and of their viability.  We hypothesized that an intraoperative tool using Elastic 
Scattering Spectroscopy (ESS) has the potential to differentiate optical signatures of the 
parathyroid gland from surrounding tissues in real-time. 
Methods:  ESS optical signatures were collected intraoperatively from perfused 
parathyroid, thyroid, fat, muscle, and nerve tissue during thyroidectomy.  The ESS data 
was collected using a portable, handheld, noninvasive, “cold” fiber optic probe able to 
detect spectra in a non-ionizing, broadband spectrum of light (320 to 920 nm).  Five 
measurements were collected at each tissue site over a total of 1.2 seconds.  Visual 
analysis of tissue was analyzed and compared to pathology, and spectral measurements 
attained with ESS. 
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Results:  No complications resulted from the use of the ESS probe.  Of the 10 
parathyroid glands evaluated to be at risk in the study, the optical probe utilizing ESS was 
able to detect unique spectral features associated with the parathyroid gland.  All 10 
parathyroid glands are optically differentiable from surrounding tissues with ESS.  
Conclusions:  Utilizing spectroscopy in the form of a hand-held probe is feasible for 
intraoperative differentiation between tissue types.  Preliminary results of this spectral 
technique warrant further investigation.  If successful, implementation of a portable ESS 
probe to identify the parathyroid tissue during endocrine surgical procedures could 
reduce surgical complications and improve patient safety.   
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INTRODUCTION 
 
The Anatomy and Embryology of the Parathyroid Gland 
 
The parathyroid glands are small endocrine glands that are usually found on the 
posterior surface of the thyroid gland.  Most humans have four parathyroid glands, made 
up of two superior glands and two inferior glands, but it is possible for supernumerary 
glands to be present.  The percentage of persons with supernumerary glands varies from 
2.5% to 22% (Orlo H Clark, Duh, & Kebebew, 2006).  Parathyroid glands can vary in 
shape as well, but remain compact in up to 98% of cases (Orlo H Clark et al., 2006).  
Each parathyroid gland has its own individual connective tissue capsule surrounded by 
fat globules, and their color depends on their adipocyte content and vascularization: light 
brown or coffee colored when the gland is very fatty, and darker, buff, or reddish brown 
when the gland is more cellular or has a richer blood supply (Akerström, Malmaeus, & 
Bergström, 1984).  The size of the parathyroid gland can vary as well, from 4 to 6 mm in 
length, and 3 to 4 mm in width, with an average, ovoid size of 5 x 3 x 1 mm.  The 
superior parathyroid glands are commonly found on the posteromedial aspect of the 
thyroid gland, which is near the tracheoesophageal groove.  The inferior parathyroid 
glands have a wider distribution, but are normally found on the inferior pole of the 
thyroid gland.  All parathyroid glands can be either extracapsular or intracapsular, relative 
to the fibrous capsule of the thyroid gland.  If a parathyroid gland is located beneath the 
capsule of the thyroid, it is deemed an intracpsular gland, if it lies outside the capsule, it 
is deemed extracapsular.   
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 Past studies have found that in 80% of cases, a single artery supplies the 
parathyroids, with a 30% chance of the artery being bifurcated, and a 5% chance of it 
branching into three distinct vessels (Orlo H Clark et al., 2006).  The vessels that supply 
superior and inferior parathyroids often branch off from the inferior thyroid artery. 
The parathyroid, thyroid, and thymus all originate from the embryonic pharyngeal 
region.  In this pharyngeal region are found 5 endodermally lined branchial pouches, 2 of 
which are crucial for parathyroid development.  The inferior parathyroid glands arise 
from the dorsal portion of the third branchial pouch, while the dorsal portion of the fourth 
branchial pouch gives rise to the superior parathyroids.  The development of the 
parathyroid glands is further divided into five stages (Orlo H Clark et al., 2006): 
 1) Preprimordial Stage- Represents the time of development from the formation 
of the pharynx to the first appearance of the embryonic parathyroid glands 
 2) Early Primordial Stage- There is proliferation and differentiation of the 
embryonic tissue that is to become the parathyroid. 
 3) Branchial Complex Stage- The branchial pouches divide across the midline, 
representing the thymus and third branchial complex (inferior parathyroids) on one side, 
and the lateral thyroid and fourth branchial complex (superior parathyroids) on the other. 
 4) Isolation Stage- Separation of each branchial complex. 
 5) Definitive Form Stage- The parathyroid glands take on their adult form. 
Other neck structures such as the thymus and thyroid gland are also involved during these 
stages, and the final location of the parathyroid glands often is due to their relation to 
those adjacent organs. 
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Function of the Parathyroid Glands 
 The parathyroid glands regulate the blood calcium levels in the body, which is 
crucial for maintaining functions such as neural transmission, bone structure, intracellular 
signaling, and blood coagulation.  There are two types of cells that make up the 
parathyroid glands: chief cells, which make the polypeptide parathyroid hormone (PTH) 
and oxyphil cells, have an unknown function at this time.  
PTH is an 84-amino acid polypeptide that is first synthesized as a pre-pro-peptide 
that is modified post translation.  25 amino acids are cut in the endoplasmic reticulum to 
create pro-PTH, a 90 amino acid peptide.  This pro-peptide is then modified again to PTH 
when the chief cell secretes the polypeptide.  The half-life of an intact PTH polypeptide is 
about 20 minutes, after which it is cleaved by Kupfer cells in the liver into 2 
polypeptides.  PTH release is dictated by calcium levels in the plasma, which are detected 
by a calcium-sensing receptor, a 7-transmembrane G protein-coupled receptor, found on 
the plasma membrane of the chief cells.  These sensors increase PTH release when they 
sense low levels of plasma calcium, and vice versa.  This calcium-sensing receptor can 
also be found in thyroid C cells and kidney tubule cells.   
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Figure 1- A diagram depicting a principal cell and the effects of calcium levels on 
PTH release. Taken from Medical Physiology: A Systems Approach, Raff and 
Levitzky, 2011. 
 
  
There are various physiological changes that can effect PTH release (see figure 1), 
all of which work to help the body regain normal calcium levels.  A decrease in calcium 
levels (hypocalcemia) quickly triggers PTH release.  This process begins with a signal 
transduction from the calcium-sensing receptor and ends with an increase in the 
expression of the PTH gene.  The opposite occurs with an increase in plasma calcium 
levels.  PTH release can also be caused by a decrease in the levels of plasma magnesium.  
Incidentally, the body’s magnesium balance is linked to that of calcium, with magnesium 
depletion often associated with hypocalcemia.  Severe hypomagnesemia (low plasma 
magnesium levels) can impair the chief cells ability to secrete PTH, and a decrease in 
both magnesium and calcium levels can impair the body’s ability to secrete PTH as well.  
An increase in plasma phosphate levels can also increase PTH secretion. 
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The physiological changes enacted by PTH are primarily seen in the kidney and 
bone (figure 2).  PTH increases the body’s plasma calcium levels through many methods, 
such as increasing renal calcium absorption, bone resorption, and, indirectly, intestinal 
calcium absorption via the active form of vitamin D.  All of PTH’s effects are mediated 
through binding to G protein-coupled PTH receptors   
 
Figure 2- The physiological effects of PTH, as well as the axis controlling its release 
from principal cells.  Taken from Medical Physiology: A Systems Approach, Raff and 
Levitzky, 2011. 
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Bone resorption is the removal of bone, and the induction of cells known as 
osteoclasts resorb bone when activated by PTH.  Osteoclasts resorb the inorganic portion 
of the bone matrix, which is mostly made up of hydroxyapatite crystals.  These crystals 
function as a reserve of calcium and phosphate, and therefore bone resorption increases 
the plasma level of both these ions.  Since bone is constantly being remodeled, 
osteoclasts and PTH play a major role in calcium homeostasis. 
 
Parathyroid Pathologies 
 In the parathyroid glands, chief cells constitute almost all of the parenchyma and 
measure 6 to 8 micrometers in diameter, and their cytoplasm contains argyrophilic 
granules and lipids (Orlo H Clark et al., 2006). There is a mixture of stromal and adipose 
elements in these glands as well, though the ratio varies with age and function.  The 
parenchyma-to-stroma ratio can be used as an indicator for a normocellular or 
hypercellular gland, with the adipose tissue content varying from 40% to 70% (Orlo H 
Clark et al., 2006).  
 Primary Hyperparathyroidism (PHPT) is an increase in the release of PTH by the 
chief cells, which leads to hypercalcemia in the blood plasma.  There are reportedly 
100,000 new cases detected each year in the United States.  There is a 2–3:1 female-to-
male distribution, and in most cases, occurrence is sporadic rather than familial (Elaraj & 
Clark, 2008).  PHPT and malignancies account for 90% of all patients with 
hypercalcemia (Orlo H Clark et al., 2006).  PHPT is distinguished from other causes of 
hypercalcemia using various laboratory tests and careful physiological examination.  
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There are three pathologic lesions known to cause the PHPT disease state: 
1) Adenoma 
2) Hyperplasia 
3) Carcinoma 
Adenomas are benign neoplasms, and in the case of the parathyroid gland, are 
composed of chief cells, oncocytic cells, transitional oncocytic cells, or a mixture of these 
different cell types.  They are responsible for 80% to 85% of cases of sporadic PHPT, and 
are usually caused by a solitary parathyroid adenoma (Elaraj & Clark, 2008).  In 
parathyroid tissue, adenomas are sometimes mistaken for hyperplastic nodules due to the 
various histological presentations of parathyroid adenomas.   
 Primary parathyroid hyperplasia is defined as an absolute increase in parenchymal 
mass in multiple parathyroid glands, in the absence of a known stimulus for PTH 
hypersecretion (DeLellis, 2011).  Parathyroid hyperplasia is also associated with a genetic 
disorder known as multiple endocrine neoplasia (MEN).  There are two types of this 
dominantly inherited disorder, both of which can result in hyperplasia of the parathyroid 
glands.  Microscopic and macroscopic analysis of hyperplastic parathyroid glands has led 
to the recognition of three hyperplastic patterns: classic, pseudoadenomatous, and occult 
(Black & Haff, 1970).  In the classic form of parathyroid hyperplasia, the parenchymal 
cells often show a nodular arrangement and are mixed with stromal elements, with a 
decrease in the amount of stromal fat cells and increase in vascular supply (Orlo H Clark 
et al., 2006). 
Because of the poor reproducibility of histologic criteria to differentiate 
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parathyroid adenoma from hyperplasia, as mentioned earlier, close cooperation between 
the pathologist and surgeon is recommended (Bornstein-Quevedo et al., 2001).  One 
helpful criteria is that in most primary chief cell hyperplasias, enlargement of more than 
two parathyroid glands is frequently observed, whereas the great majority of adenomas 
involve a single gland (Orlo H Clark et al., 2006).  Figure 3 compares the histological 
appearance of a hyperplastic parathyroid, adenoma, and parathyroid carcinoma.   
 
Figure 3- Histological appearance of parathyroid adenoma, carcinoma, and hyperplasia. 
From left to right: hyperplasia and adenoma.  Bottom image, parathyroid carcinoma.  
Images taken from http://library.med.utah.edu 
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Parathyroid carcinoma is responsible for .5% to 2% of cases of PHPT (Orlo H 
Clark et al., 2006).  Parathyroid carcinomas are a poorly defined mass, unlike the obvious 
shape of an adenoma, and adhere to the surrounding tissues.  This characteristic 
invasiveness often helps physicians differentiate between parathyroid carcinoma and 
adenoma.  Microscopically, a parathyroid carcinoma consists of neoplastic parenchymal 
cells that show atypia, mitotic figures, capsular and vascular invasion, and, of paramount 
importance, thick fibrous bands interspersed among the neoplastic cells (Orlo H Clark et 
al., 2006).  However, all of these features may not be seen in every parathyroid carcinoma 
case, and may also be present in other disease states.  Of the features noted, the one seen 
most often are the fibrous bands, present in 90% of parathyroid carcinoma cases and 
visible in the bottom image of figure 3 (Orlo H Clark et al., 2006). 
 
Secondary and Tertiary Hyperparathyroidism  
 Secondary hyperparathyroidism (SHPT) occurs with excessive secretion of PTH 
response to hypocalcemia.  The increased secretion of PTH leads to hypertrophy of the 
parathyroid glands.  SHPT may develop in response to a multitude of pathologic states, 
including declining kidney function, impaired phosphate excretion, and failure to 
bioactivate vitamin D (Cunningham, Locatelli, & Rodriguez, 2011).  Renal dysregulation 
is a major cause of secondary hyperparathyroidism.  Dysregulation of calcium and 
phosphorous homeostasis leads to decreased renal phosphate excretion, increased serum 
phosphorous, and reduced synthesis of the active form of vitamin D (Cunningham et al., 
2011).  If a patient’s SHPT is poorly controlled, it can lead to bone disease and soft tissue 
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and vascular calcification- disease states that can influence morbidity and mortality 
(Cunningham et al., 2011).  
Tertiary hyperparathyroidism can be described as a state of excessive secretion of 
PTH, and occurs after an extended period of SHPT.  Tertiary hyperparathyroidism results 
in hypercalcemia.    Therapeutic intervention to treat secondary and tertiary 
hyperparathyroidism can be difficult because of the challenges of lowering PTH while 
simultaneously controlling serum levels of calcium and phosphorus (Cunningham et al., 
2011).             
 
Multiglandular Parathyroid Disease 
 Multiglandular hyperparathyroidism is defined as the presence of 2 or more 
enlarged glands weighing more than 50 mg (Proye et al., 1998).  Preoperative 
biochemical and imaging studies are needed to reliably distinguish single-gland versus 
multigland parathyroid disease (Kebebew, Hwang, Reiff, Duh, & Clark, 2006).  Initial 
operations for PHPT due to multiglandular disease should consist of conservative 
surgery.  Proye and associates describe this as identification of all four parathyroid 
glands, followed by removal of only the grossly enlarged glands without biopsy of the 
other glands.   
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Ectopic Parathyroid Glands 
 Ectopic parathyroid glands can be found in various areas of the neck and 
medialstinal regions.  Ectopic glands are attributed to abnormal migration during 
embryogenesis, and because the inferior parathyroid glands undergo more extensive 
migration during embryogenesis, they are more likely to be found in ectopic locations.  
Ectopic superior parathyroid glands are likely due to pathological displacement from a 
normal anatomic position (Phitayakorn & McHenry, 2006).  The most common site of an 
ectopic inferior parathyroid gland is the intrathymic region, and the most common site of 
an ectopic superior parathyroid gland is in the tracheoesophageal groove (Phitayakorn & 
McHenry, 2006).  In the study conducted by Phitayakorn and McHenry in 2006, out of 
231 patients operated on for hyperparathyroidism, 37 (16%) had an abnormal ectopic 
parathyroid gland, leading them to suggest that abnormal ectopic parathyroid glands may 
be more common than previously reported.   
 
Rationale for Parathyroidectomy 
 The clinical picture of PHPT has changed in recent decades, and many patients 
are now diagnosed through the finding of high serum calcium levels (Cipriani et al., 
2014).  PHPT is the most common cause of hypercalcemia in outpatients, while 
malignancy is the most common cause of hypercalcemia in hospitalized patients (O H 
Clark & Duh, 1989).  In April 2002, the NIH met to re-evaluate the recommendations for 
surgery for PHPT, where the following revised recommendations for surgery were 
decided.  This list is taken from the Textbook of Endocrine Surgery. 
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1) Serum calcium greater than 1 mg/dL (0.25 mM) above the upper reported 
normal reference range. 
2) 24-hour urine calcium excretion 400 mg/day 
3) A 30% decrease in creatinine clearance compared with age-matched subjects 
4) Bone density at the lumbar spine, hip, or distal radius greater than 2.5 SD 
below peak bone mass (T-score less than -2.5) 
5) Age younger than 50 years. 
6) Patients for whom medical surveillance is not possible or desirable. 
There is good evidence that in about 80% of patients the clinical manifestations improve 
after successful parathyroidectomy, and as such there is improvement in symptoms such 
as fatigue, bone and joint pain, and polyuria, among others (Orlo H Clark et al., 2006).   
 Manifestations of PHPT, as well as secondary and tertiary hyperparathyroidism 
can be safely said to warrant medical evaluation, which in most cases leads to a 
parathyrodiectomy operation.  Parathyroidectomies, when performed by an experienced 
surgeon, are successful in more than 95% of patients, and it is the major treatment for 
PHPT (Orlo H Clark et al., 2006).  Parathyroidectomies also take less than 2 hours, 
usually do not require blood transfusions, have minimum complications (seen in less than 
2% of patients), and usually only require hospitalization for 24 hours (Orlo H Clark et al., 
2006).  
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Parathyroidectomy Techniques 
 The parathyroid glands are quite small and found in varied locations in the neck 
prompting the surgeon Edward D. Churchill to state that “the success of parathyroid 
surgery must lie in the ability of the surgeon to know a parathyroid gland when he sees it, 
to know the distribution of the glands, where they hide, and also to be delicate enough in 
technique to be able to make use of this knowledge.”  These fundamentals of parathyroid 
surgery still hold true, and a firm grasp on the embryology and anatomy of the glands is 
essential for a successful parathyroidectomy to take place.  In other words, the gold 
standard for parathyroid surgery is surgical judgment.   
Before submitting a patient to surgery, a surgeon must make a sound diagnosis of 
hyperparathyroidism by assessment of an elevated serum PTH level using a two-site 
immunoassay (Hackeng, Lips, Netelenbos, & Lips, 1986)(Blind, Schmidt-Gayk, 
Armbruster, & Stadler, 1987)(Frölich, Walma, Paulson, & Papapoulos, 1990).  The 
surgery is done under general anesthesia with endotracheal intubation.  The patient is 
positioned in such a way that the neck is hyperextended, so that the surgeon may make an 
incision in such a way that it will not become a hypertrophic scar.  The surgical field 
should also be kept as bloodless as possible.  This prevents discoloration of the 
parathyroid glands, which would impede their identification (Orlo H Clark et al., 2006).  
The parathyroid glands are often surrounded by lobules of fat, so the surgeon should be 
inspecting any lobules that may be present for parathyroid glands.  Another feature a 
surgeon may make use of during a parathyroidectomy is the relative freedom of motion 
of the parathyroid glands in relation to the thyroid gland (Orlo H Clark et al., 2006). 
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During the procedure, preservation of the vessels supplying the parathyroid glands 
is essential to prevent damage to the glands that are functioning normally.  Dissection of 
the upper parathyroid gland should begin at the dorsal tip of the upper parathyroid to 
prevent injury to the parathyroid vessels, which usually ascend from the inferior thyroid 
artery, while dissection of the inferior gland should start at the caudal end (Orlo H Clark 
et al., 2006).  Parathyroid exploration usually begins by searching for the right upper 
parathyroid gland, and the surgeon must take care as to prevent injury to the recurrent 
laryngeal nerve, which runs anteriorly and medially to the upper parathyroid gland.   
The reason a surgeon must remain aware of the position of the recurrent laryngeal 
nerve is because it controls all intrinsic muscles of the larynx, except for the cricothyroid 
muscle (“Laryngeal Nerve Anatomy,” 2013).  The cricoarytenoid muscles work to open 
and close the vocal cords, and include the posterior cricoarytenoid muscle, the only 
muscle that opens the vocal cords.  Injury to the nerve could paralyze the posterior 
cricoarytenoid muscle, causing dyspnea.  Injury to both the right and left recurrent 
laryngeal nerve may result in more serious damage, such as the inability to speak. 
Past studies have shown that patients with nonfamilial hyperparathyroidism or 
MEN should only have enlarged parathyroid glands with an estimated weight greater than 
40 mg removed (Bonjer et al., 1992).  Patients with a solitary enlarged parathyroid gland 
should have the vascular stalk of the tumor ligated and the tumor removed (Orlo H Clark 
et al., 2006).  If multiple glands are enlarged, they should be removed.  In patients with 
secondary hyperparathyroidism, familial hyperparathyroidism, or MEN 1, all of the 
parathyroid glands are involved, and the rate of recurrent hyperparathyroidism ranges 
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from 10% to 50% (Orlo H Clark et al., 2006).  In these cases, a subtotal 
parathyroidectomy is performed, which leaves behind a vascularized remnant of a lower 
parathyroid gland, with dimensions similar to that of a normal functioning gland.  If the 
parathyroidectomy is successful, a decrease in the serum calcium levels will be seen, and 
should reach normal levels about 48 hours after the operation (Orlo H Clark et al., 2006). 
 
Parathyroid Reoperations 
As discussed earlier, the cure rate for HPT after a successful operation is very 
high (95%).  However there are cases, though few, where an operation for HPT requires a 
cervical re-exploration.  HPT following a prior operation for hypercalcemia can be 
divided into two subtypes: persistent (hypercalcemia recurring within 6 months after the 
operation) or recurrent (hypercalcemia recurring after 6 months of normocalcemia 
following the initial operation) (Clark, Way, & Hunt, 1976)(Brennan & Norton, 1985).   A 
persistent HPT is considered to be a missed pathology, while recurrent HPT is the result 
of a newly developed pathology.   
It has been estimated that 2% to 10% of surgical failures may be attributed to an 
incorrect diagnosis (Marx et al., 1980).  A surgical failure can be due to a great number of 
things: lack of knowledge concerning parathyroid anatomy and embryology, inability to 
recognize an abnormal gland, failure to locate ectopic glands, incomplete removal of 
diseased gland or glands, and other causes.  It has been noted that up to 37% of patients 
who are need of a parathyroid reoperation have multiple-gland disease rather than a 
single adenoma (Clark et al., 1976).   
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Due to these varying, complex factors that accompany patients who need a 
reoperation, and the fact that the success rate of parathyroid reoperations are 10% to 15%  
lower than primary procedures, the surgeon and endocrinologist must be unequivocally 
sure that the patients has HPT before beginning the complex route of reoperation (Orlo H 
Clark et al., 2006). 
 
Minimally Invasive Parathyroid Surgery 
In recent years, there have been several techniques developed for minimally-
invasive parathyroidectomies.  Such techniques include open minimally-invasive 
parathyroidectomy (OMIP), minimally-invasive radio-guided parathyroidectomy (MI-
RP), and pure endoscopic parathyroidectomy (EP) (Bellantone et al., 2011).  Bilateral 
neck exploration (BNE) with identification of at least four parathyroid glands and 
subsequent removal of pathologic parathyroid tissue has been the gold standard for the 
treatment of PHPT (Bellantone et al., 2011).  Though this operation has a greater than 
95% success rate, the rationale for developing less invasive procedures comes from the 
fact that most patients (>85%) with PHPT have only single parathyroid adenoma that is 
potentially removable with a more selective surgery (Bellantone et al., 2011).  
Trials comparing minimally-invasive parathyroidectomies with standard BNE 
have been performed by Bergenfelz and Westerdahl in 2002 and 2007.  These studies all 
demonstrated that unilateral neck exploration is associated with a shorter operative time 
and the same cure rate at short and long-term follow-up (Bergenfelz, Lindblom, Tibblin, 
& Westerdahl, 2002)(Westerdahl & Bergenfelz, 2007).  OMIP can then be considered as 
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an initial, safe, and cost-effective surgical option for the treatment of the percentage of 
patients with PHPT, especially since single-gland excision through MIP does not imply 
an increased risk of persistent or recurrent PHPT when compared to BNE (Bellantone et 
al., 2011).     
 
Surgical and Technical Difficulties Involved with Parathyroid Surgeries 
 Even with the high success rate of parathyroidectomies, a pathologic parathyroid 
gland may go undiscovered in some circumstances after routine neck exploration.  In 
such cases, a surgeon must identify the normal glands in their normal locations, and 
explore known regions for parathyroid glands to be found if one is missing from its 
normal location.  Usually, enlarged glands can be selectively removed, and the rate of 
recurrent hyperparathyroidism after removal is around 1.8% at a rate of follow-up of 13.5 
years (Bonjer, Bruining, Bagwell, Jones, & Nishiyama, 1992).  
   In the case of a parathyroid tumor, the surgeon must take care as to not rupture 
the capsule of the parathyroid gland to prevent seeding of parathyroid tissue, which can 
cause recurrent hyperparathyroidism (Akerström, Rudberg, Grimelius, & Rastad, 1988).  
If recurrent hyperparathyroidism does occur, a reoperation is usually the course of action. 
 A successful parathyroidectomy is not without its difficulties.  Postoperative 
hypocalcemia can occur, most often in patients with severe skeletal depletion of calcium, 
resulting in “bone hunger” (Orlo H Clark et al., 2006).  If left untreated, hypocalcemia 
can result in numbness of the mouth, muscle cramps, convulsions, tingling of the 
fingertips, and other symptoms.  Treatment is administered calcium, and patients should 
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be given a (maximum) of 3 g of calcium orally per day.  If this treatment is ineffective, 
alfacalcidol (a derivative of vitamin D) should be added to the oral calcium medication.  
If a patient is experiencing tetany (involuntary contraction of the muscles), intravenous 
calcium may be used (Orlo H Clark et al., 2006). 
 Reimplantation of parathyroid tissue can be used as an alternative to a subtotal 
parathyroidectomy.  In these cases, cryo-preserved parathyroid tissue is autotransplanted 
into the forearm muscle (Orlo H Clark et al., 2006).  However, a French multicenter study 
performed in 2010 found that the success of reimplantations is low, and found that out of 
22 patients who had undergone autgrafting of parathyroid tissue, only 2 autografts (10%) 
were fully functional, 2 (10%) were partially functional, and 17 (80%) were 
nonfunctional at 26 months median follow-up (Borot, Lapierre, Carnaille, Goudet, & 
Penfornis, 2010).  A similar study by Ito et al in 2014 discussed how to avoid permanent 
hypoparathyroidism after completion of total thyroidectomy (after a previous 
hemithyroidectomy was initially performed), and found that 8 of 154 patients showed a 
permanent hypoparathyroidism if they did not undergo autotransplantation of parathyroid 
tissue (Ito, Kihara, Kobayashi, Miya, & Miyauchi, 2014).  The study concluded that 
careful searching and preservation of the parathyroid glands is essential, and that if they 
are dissected they should be retrieved and autotransplanted to save the patient from 
permanent hypoparathyroidism (Ito et al., 2014).  The literature seems divided on the 
subject, and future research will need to be conducted in order to see how effective 
reimplantation truly is.          
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Thyroidectomies and the Parathyroid Gland 
The thyroid gland is located just below the laryngeal prominence in the neck.  It is 
one of the body’s largest endocrine glands, and has many functions, including making 
proteins, regulating other body hormones, and controlling metabolism.  The thyroid gland 
is responsible for producing two specific hormones:  triiodothyronine (T3) and thyroxine 
(T4 ).  The production of T3 and T4 is regulated by a hormone produced by the anterior 
pituitary gland called thyroid-stimulating hormone (thyrotropin or TSH).  The body has 
set up a negative-feedback loop between the amounts of TSH and T4 production to 
regulate normal body functions.  Dysregulation of the thyroid hormones can lead to 
hyperthyroidism and hypothyroidism.  Thyroid neoplasms can also occur.  
Thyroidectomies are often performed by a surgeon when a patient has thyroid cancer, or a 
dysregulation of thyroid hormone as mentioned above.        
Postoperative hypocalcemia is the most frequent complication of total 
thyroidectomy (Puzziello et al., 2014).  In a multicenter study done by Puzziello et al in 
2014, which included 2,631 patients, the incidence of hypoparathyroidism was 28.8% 
(757 patients).  That 28.8% included both transient and permanent hypocalcemia, with 
27.9% being transient and .9% being permanent hypocalcemia (Puzziello et al., 2014).  
This study helps confirm the importance of surgical judgment in the identification of 
parathyroid glands during cervical surgeries to prevent transient, and in some cases 
permanent, hypocalcemia. 
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Elastic Scattering Spectroscopy  
Elastic Scattering Spectroscopy (ESS) is a useful optical tool for understanding 
matter by its interaction with electromagnetic radiation.  In the case of biomedical 
applications of ESS, cells and subcellular structures play the role of microscopic optical 
resonators (Perelman, Modell, Vitkin, & Hanlon, 2013).  “When light enters the tissue of 
interest, it can take many paths, and may be elastically scattered, inelastically scattered, 
or absorbed (Jerjes, Swinson, Pickard, Thomas, & Hopper, 2004).”  The cell is a complex 
structure and has a broad range of scatterer sizes, from a few nanometers to the size of the 
cell itself (Perelman et al., 2013).  Experiments focusing on the influence of cell 
morphology on the scattering pattern of light have found that the internal structure of an 
organelle does affect the scattering at larger angles, but not in the forward or backwards 
directions (Drezek, Dunn, & Richards-Kortum, 1999).  This is because the smaller 
structures within the organelles scatter intensely in the intermediate angles, while light 
scattering in the forwards or backwards direction depends on larger structures, such as an 
organelle (Perelman et al., 2013).  The incident light can undergo single, or more 
commonly, multiple scattering events before being collected again at the same surface by 
an optical probe and the resulting data is analyzed (Sharwani et al., 2006).   
The light utilized by ESS is known as broadband light (~320 to 920 nm).  
Broadband light is non-ionizing, and has no known negative side effects.  This process 
potentially allows for minimally invasive and objective real time diagnosis in an 
operator-independent manner. (Mourant, Johnson, Los, & Bigio, 1999) 
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 ESS has already been shown to provide optically distinct spectra in other tissues 
of the body, including differences between benign and malignant tissues.  ESS has 
already been used to detect oral cavity lesions, Barrett’s esophagus, discriminate between 
benign and malignant thyroid nodules, colonic polyps,  bladder cancer and other organs  
(Sharwani et al., 2006) (Zhu et al., 2009) (Rosen et al., 2013) (Dhar et al., 2006) 
(Mourant et al., 1995).  According to the literature, the current gold standard 
intraoperative method for identifying parathyroid glands is surgical judgment, and we 
hypothesize that an intraoperative probe utilizing ESS has the potential to differentiate 
the optical signatures of the parathyroid gland from surrounding tissues in real-time.        
In our study, we will be using ESS intraoperatively to identify optical signatures of 
parathyroid, thyroid, nerve, blood vessel, fat, and muscle tissues.   
 
Figure 4: A graphic demonstrating how light scatters upon interaction with tissue.  Note 
the difference in diameter between the source and detector fiber. Figure based on the 
cartoon found in Mourant et al. 1997. 
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As seen in the diagram above, the setup of our probe consists of two fiber optic 
probes placed directly next to each other. This pair of fiber optic cables is placed in direct 
contact with the tissue of interest.  A light source attached to the source fiber then emits 
photons, which travel down the fiber optic cable and interacts with the tissue.  As 
discussed above, a photon may interact with tissue in a variety of ways, but for our probe, 
we are interested in what happens when a photon is scattered.  Our detector probe is able 
to measure when a photon is scattered back to its fiber optic cable, which carries the 
photon back to a spectrometer.  The scattered photon carries information about the path 
it’s traveled, and when the pathlength of photon travel is known, Beer’s law can be used 
to determine the absorption coefficient (Mourant, Johnson, Los, & Bigio, 1999).  The 
pathlength of photon travel in a scattering medium generally depends on the scattering 
parameters of the medium (Mourant et al., 1999).  In a previous study conducted by 
Mourant et al. in 1997, it was demonstrated that for an appropriate scope of fiber 
separations, between light delivery and collection fibers, the pathlength of the collected 
photons, L, is insensitive to variations in scattering parameters for the range of scattering 
parameters typically found in tissue.  This precise optical geometry allows us to gather 
data from a larger number of photons, and therefore compile and display a more precise 
spectrum for each tissue type. 
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SPECIFIC AIMS 
 
The specific aims of this project are as follows: 
1) Conduct an intraoperative in vivo clinical trial 
2) Utilize a specially-designed “parathyroid probe” which incorporates the 
optical geometry used in previous ESS experiments. 
3) Use spectral data to discriminate parathyroid tissue from surrounding tissue, 
and malignant tissue when relevant. 
4) Correlate the data with pathological evaluation if needed. 
This project is an expansion of the work done by Rosen et al, who utilized an ESS 
probe in FNA thyroid biopsies in the discrimination of benign from malignant disease in 
thyroid nodules with indeterminate cytology (Rosen et al 2013).  This study did change 
the diameter of the source and fiber detectors, choosing to use a 150 µm source and 100 
µm detector fiber.  This optical geometry is based off the second generation thyroid 
probes utilized by Rosen et al, and allowed us to construct a probe that would be feasible 
for intraoperative use.  While the current set of patients utilizes the ESS system set in 
place by Rosen et al, a new ESS system for future patients in this study is being tested by 
Dr. Irving Bigio’s laboratory at Boston University that will allow for measurements to be 
taken over a shorter length of time. 
 The parathyroid gland spectral data collected by the ESS probe will be analyzed 
and compared against the spectral data of its surrounding tissue, in order to determine if 
there are distinct optical signatures for parathyroid gland spectra.  
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MATERIALS AND METHODS 
ESS System 
 The following description of the ESS system is taken from Rosen et al, as this 
study utilized the exact same ESS instrumentation.  “The ESS instrumentation consists of 
a pulsed xenon arc lamp, an optical probe, a spectrometer, and a computer to control the 
various components and record the spectra (see figure 5). ESS involves directing short 
pulses (~1 ms) of white light (~320 to 920 nm) from the pulsed xenon arc lamp (Perkin 
Elmer, Inc., Fremont, California) through a flexible emission optical fiber (200 micron 
diameter, for this study) touching the tissue to be interrogated. Ultraviolet B (280 to 315 
nm) and ultraviolet C (100 to 280 nm) light are filtered out to avoid any potential risk to 
patients. A collection fiber (also 200 micron diameter, for this study), with a fixed 
separation distance of 250 μm from the first fiber (center to center), collects light 
scattered from the nearest layers of the tissue and propagates it to the spectrometer 
(S2000 Ocean Optics, Dunedin, Florida), which outputs the spectrum to the laptop 
computer for recording and further analysis. The whole fiber assembly measures 1.5 mm 
in diameter, and the distal end is housed in a rigid stainless steel casing for easy handling 
and sterilization.” The collection and recording of a single spectrum takes less than a 
quarter of a second, with the integration time of the detector being the limiting factor.  
The difference in our study is that the fiber optic setup includes a 150 μm source fiber 
and a 100 μm detection fiber. 
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Figure 5: An image of the first generation portable ESS system. 
 
 
 There is current testing being done by Dr. Bigio and his laboratory at the Boston 
University Photonics Center on a new generation of this ESS system.  The new system 
has an updated voltage source, significantly decreased integration time, spectrometer, and 
software.  The voltage for the new system is between 700V and 1000V, where changing 
the voltage changes the energy per pulse. Testing showed that the integration time of the 
new system varied from 20 microseconds to 60 microseconds, a major decrease in 
integration time from the first generation system.  The new software, called BioSpec, is 
also capable of using dark subtraction, which helps remove light that can interfere with 
the fiber optic probe’s measurements.  The shorter integration time and upgraded dark 
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subtraction allow the ESS technician to not have to worry about the overhead surgical 
lamps light interfering with the collection of tissue spectra, or bringing a cover for the tip 
of the probe.  The updated ESS system is also capable of taking a group of measurements 
over a short amount of time, known as a sequence.  For our study, a sequence of 
measurements will be kept to 3 separate “pulses” of light being sent through the fiber 
optic.  The images obtained from each pulse can then be averaged to increase the 
resolution of the acquired spectra.  The system is able to take these 3 measurements 
within that shortened integration time, dramatically decreasing the amount of time the 
surgeon has to operate the probe during surgery as well as the amount of time overhead 
light has to interfere with the measurements.   
 The updated system also contains a more sensitive sensor with a greater bit depth.  
The depth of the sensor determines how much information per data point you are able to 
store, which gives you a higher resolution spectra.  The first generations ESS system has 
a 12 bit sensor, while the upgraded system has a 16 bit sensor.  A bit depth of 16 also 
increases the dynamic range that the system is able to consider.  The dynamic range is the 
ratio between the largest and smallest possible values of a signal, in our case, light.  It is 
measured in base-2 (bits).  For example, the 16 bit sensor has a dynamic range of 2
16
, or 
65,536 bits.  We utilize 80% of the dynamic range in our study with both the 12 bit and 
16 bit sensors. 
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ESS System Calibration  
 Before tissues spectra can be analyzed, a reference spectrum must be taken.  This 
establishes the overall system response by recording the diffuse reflectance from a flat, 
white surface of Spectralon™ (Labsphere, Inc., North Sutton, NH), which has spectrally 
flat diffuse reflectance between 250 and 1000 nm (Rosen et al., 2013).  Taking a 
reference spectrum before attempting to obtain tissue spectra allows spectral variations in 
the light source, fiber transmission, spectrometer, and fiber coupling to be accounted for 
(Rosen et al., 2013).  The reference is also taken so that the signal is 80% of the total 
number of counts.  For a 12 bit sensor, the total number of counts is 2
12
, and for a 16 bit 
sensor the total number of counts is 2
16
.  A reference spectrum allows the ESS system 
operator to observe, in real-time, the spectra of the tissues inspected by the probe.  
Further analysis would have each tissue spectra divided by the reference spectrum to 
obtain the system-independent reflectance spectrum of the site being investigated.   
 
Data Collection and Acquisition of Spectra  
For the intraoperative, in vivo experiment using the 150 source µm and the 100µm 
detector fibers, subjects were recruited (n=5) under IRB approval from Boston Medical 
Center.  A recruitment of n=5 subjects so far has led to a preliminary evaluation of 10 
parathyroid glands.  These subjects were recruited from the endocrine surgery department 
at Boston Medical Center.  Before undergoing surgery, the surgeon performing the 
surgery obtained informed consent from the patient after explaining the details of the 
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surgery, treatment plan, complications, risks of the surgery, etc.  The fiber optic probes 
were sterilized in the central processing department using ethylene oxide.  Once the 
patient had been anesthetized, the ESS system operator brought the portable instrument 
into the room and the sterilized probe is handed to the surgical technician.  The surgeon 
then can use the probe within the sterile field throughout the surgery at his/her discretion.  
The probe should be placed on perfused parathyroid and thyroid tissue, along with any 
fat, muscle, nerve, and blood vessels that are visible.   
When the surgeon finds a tissue suitable for spectral analysis, the surgeon signals 
the ESS technician, who then can trigger the spectrometer to obtain a spectral 
measurement.  Five measurements are taken at each tissue site, over a span of about 5 
seconds.  At the surgeons’ discretion, the overhead surgical lights were also turned off in 
order to collect tissue spectra that were not saturated with the light of the overhead lamps, 
a problem that will be nonexistent with the upgraded system due to the better dark 
subtraction software and a much shorter integration time (20-60 microseconds). 
A small, sterilized, black, rubber “cover” was developed and placed over the tip of 
the probe for patients 4 and 5 in order to block the surgical lamps from interfering with 
the measurement.  Measurements were taken at the same site with the lights on/off and 
the probe cover on/off.  After the spectral data was acquired, the optical probe was 
returned to the ESS technician and the surgery continued as normal.  Normal pathological 
processing occurred from this point forward.  The subjects are then de-identified and the 
collected spectral data is differentiated between tissue types. 
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Subject Inclusion Criteria 
 Subjects were of both genders, ranging from 18 to 64 years of age, and were 
comprised of all ethnic groups.  The subject had to speak either English or Spanish in 
order to be included in the study.  No children were allowed into the study.  Subjects had 
to be undergoing cervical surgery, usually thyroidectomy, parathyroidectomy, or bilateral 
neck exploration. 
 
Subject Exclusion Criteria 
 Subjects with infectious diseases, including HIV, were not allowed to participate 
in the study.   
 
Spectral Analysis 
The five measurements taken at each tissue site were averaged.  This was done in 
order to improve the signal-to-noise ratio of the spectra. All spectra were then pre-
processed by cropping, smoothing and normalizing before analysis.  Graphically, the 
spectra were depicted comparing wavelength on the X-axis and ESS normalized 
intensities on the Y axis.  The normalized intensities are measure in arbitrary units.  A 
leave-one-out cross-validation was used to obtain a value of sensitivity and specificity for 
the ESS probe compared to the “gold standard” of surgical judgment. 
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RESULTS 
 
 Boston Medical Center’s Internal Review Board approved the preliminary clinical 
study, in which 5 patients have been enrolled so far.  The results of the 5 patients in 
respect to the detection of parathyroid tissue with ESS are shown below.  There have 
been varied surgeries in this preliminary study: 1 papillary thyroid cancer (PTC) in the 
thyroid isthmus requiring thyroidectomy, 2 patients with Grave’s disease requiring 
thyroidectomy, and 2 multinodular goiters requiring thyroidectomy.  Out of these initial 
five operations, only two required reimplantation of parathyroid tissue.  The leave-one-
out analysis below (table 1) demonstrates the specificity and sensitivity of ESS when 
compared to the gold standard of surgical judgment.  
 
Table 1 
 
 
 
Surgical Judgment 
E
S
S
 M
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Parathyroid Tissue Non-Parathyroid 
Tissue 
Parathyroid Tissue           
         6 
 
                  1 
Non-Parathyroid 
Tissue 
 
         1 
 
                 5 
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The spectra are analyzed in the region from 320 to 820 nm.  This is the optimal 
wavelength due to the noise pollution seen in the spectra above 820 nm and below 320 
nm.  Data was first divided by the reference spectra in order to account for the system 
response.  Data was further normalized to the area under the curve for each spectrum.  
Any data that was saturated was also removed from analysis.  This includes spectra that 
were saturated by the overhead surgical lights, and data that was affected by strong 
hemoglobin absorption.   
 The data collected from the first patient was excluded from table 1, as all data 
collected from that patient showed signs of saturation from the overhead lights.  Data 
from patients 2 through 5 were included in the calculations.  The preliminary 
intraoperative in vivo study (n=5) found that ESS was 83% specific in identifying 
parathyroid tissue against the gold standard of surgical judgment.  A greater number of 
patients will need to be recruited into the study to validate the statistical analysis.  
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Figure 6- Spectral comparison of all parathyroid glands measured in the preliminary 
study.  All data has been individually normalized to the area under the curve.  The 
average of all parathyroid spectra is also included (black). 
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Figure 7- Spectral comparison of normalized thyroid gland ESS spectra.  Note the 
averaged spectrum of the thyroid tissue is included (black). 
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Figure 8- Comparison of the normalized averaged parathyroid and thyroid spectra from 
the first five subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-0.0005 
9E-18 
0.0005 
0.001 
0.0015 
0.002 
0.0025 
320 420 520 620 720 820 
ES
S 
N
o
rm
al
iz
e
d
 In
te
n
si
ti
e
s 
(a
.u
.)
 
Wavelength (nm) 
Parathyroid Averages Thyroid Averages 
  35 
 
Figure 9-An example of normalized ESS spectra of muscle tissue in patient 5. 
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Figure 10- Plot of parathyroid tissue average against muscle tissue.  All values are 
normalized to the area under the curve. 
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Figure 11- Sample ESS spectrum of a fat deposit in the neck of subject 2.  Notice the 
absorption at ~460 nm that is consistent with beta-carotene absorption. 
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Figure 12- A comparison of two thyroid spectra.  Note that the spectra taken in patient 5 
are of a perfused, or oxygenated thyroid tissue, while that of patient 2 is deoxygenated.   
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DISCUSSION  
  
 
 The preliminary results from the intraoperative use of the ESS parathyroid probe 
have shown, upon inspection of the normalized spectra, that there is a distinction between 
parathyroid tissue and surrounding tissue in the neck.   
Upon initial visual inspection of the spectra, there are many distinct signatures 
that can be seen.  The spectral differences in the ultraviolet region (320 to 400 nm) are 
consistent with a phenomenon known as Rayleigh scattering, which assumes that photons 
are elastically scattered from extremely small particles compared to the wavelength, and 
tells us that the shorter the wavelength, the greater the scattering (Mulvey, Sherwood, & 
Bigio, 2009).  The amplitude of the spectra, shape of the spectra, and ratios of different 
peaks could all tell surgeons important information about the tissue of interest. 
Of important note is the differentiation between oxygenated and deoxygenated 
tissues and the ability of ESS to detect hemoglobin saturation.  Hemoglobin saturation 
can be indicated by a large absorption (a trough on the spectra) at approximately 420 nm, 
as well as two small troughs, known as the alpha and beta q bands, at 540 and 580 nm.  
Figure 12 showcases the differences that can be seen between thyroid tissue that is 
perfused (and thus is saturated with oxygenated hemoglobin) and thyroid tissue that is 
underperfused.  The second graph of figure 12 clearly shows a lack of the two smaller 
troughs at 540 and 580 nm, as well as a less intense trough at 420 nm.  This visually 
distinct optical signature of hemoglobin is important, as a technician can advise a surgeon 
as to when a tissue site is underperfused, or if the hemoglobin absorption is too strong.  
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Hemoglobin absorption can override the signature of the tissue the technician is trying to 
obtain, meaning that the technician needs to inform the surgeon and have him/her either 
move the probe to another location at the tissue site, clean the current site with saline 
solution, or clean the tip of the probe with a saline solution to remove excess hemoglobin. 
Another interesting spectral shape is the trough made by the absorption of beta-
carotene, the absorption spectrum of which can be seen in figure 13.  If we compare this 
absorption spectrum to the flattened “peak” seen in figure 11, there is a clear dip 
(between 400nm and 500nm) where the beta-carotene absorption spectrum is peaking,  
The prominence of the beta-carotene absorption could help future surgeons easily 
identify fat surrounding the parathyroids and other tissues. 
 
Figure 13- Beta-carotene absorption spectrum. After Vetter et al. in Carotenoids (ed. O. 
Isler), Birkhauser Verlag, 1971 , p194 
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Further analysis involved normalizing the data to the area under the curve.  The 
averaged data for the parathyroid, thyroid, muscle, and fat spectra was normalized in 
order to allow for cross-patient analysis of the same tissue types.  Figures 8 and 10 show 
the optical differentiation that can be obtained with area under the curve normalization 
techniques.  From looking at the normalized averages of parathyroid compared to thyroid, 
the parathyroid seems to be less perfused with oxygenated blood and it scatters more at 
the shorter wavelength (<350 nm). There is a similar difference between parathyroid and 
muscle, though there is less of a difference in perfusion and only a single muscle 
spectrum to compare against.  The slope between 360 nm and 500 nm, as shown in figure 
14, shows a negative slope for the parathyroid and a positive slope for the thyroid, a 
difference that can be distinguished by visual inspection alone. 
Since this is a preliminary empirical study, the exact cellular and subcellular 
components that cause the distinct scattering patterns are still unknown.  Visual 
inspection of the averaged, normalized did suggest that there is a unique optical signature 
for different tissues in the neck, especially between parathyroid and thyroid.  Any data 
that was affected by either strong hemoglobin absorption or saturated with overhead light 
was not used in the normalization analysis to allow for clear analysis of the normalized 
averages. 
The repeatability of ESS measurements can be seen in figures 6 and 7.  The 
spectra obtained for the parathyroid glands in particular shows a consistent, distinct 
optical signature over multiple patients.   
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Figure 14- Comparison of the normalized averaged parathyroid and thyroid spectra.  
Lines are included to highlight the differences in slope between parathyroid and thyroid 
spectra.  
 
 
 
As demonstrated, studying the amplitude of the spectra, distinct signatures, and 
the amount of pulses released from the light source, ESS is able to provide one with the 
ability to define distinct optical signatures of different tissues.  Preliminary results 
indicate that future applications of the ESS probe in intraoperative surgeries could greatly 
benefit the surgeon in identifying different tissues. 
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CONCLUSION 
ESS spectroscopy was found to be an effective method for identifying parathyroid 
glands intraoperatively during endocrine surgeries.  The preliminary results suggest that 
there is indeed a unique optical signature for the parathyroid gland, and that it is visually 
distinct from thyroid, muscle, and fat tissues.  Although the current ESS system has an 
integration time that is too long, and therefore causes overhead light to saturate the 
spectra, the introduction of a black rubber cover, as well as remove of the overhead light, 
helped eliminate this saturation.  The new generation ESS system has a greatly reduced 
integration time as well as more advanced dark subtraction software, allowing us to 
forego the use of a rubber cover on the tip of the probe, and surgeons will no longer have 
to turn off the overhead lights (a procedure that most surgeons would not be comfortable 
with).   
The study is scheduled to continue obtaining data from endocrine surgeries with 
the new ESS system, and we hope it will yield more precise data on the different tissues.  
We believe that this research will help surgeons identify the parathyroid glands with 
greater accuracy, in order to preserve them so as to avoid hypocalcemia and the issues 
associated with reimplantation of parathyroid tissue.  We hope that this research and 
technology will provide future surgeons with an effective, portable device that can be 
easily wielded in the operating room, and provide real-time feedback on any tissue under 
investigation 
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